Latest News

ETAP-Lab est à la recherche d’un(e) « PROSPECTEUR(TRICE) COMMERCIAL(E)». Pour accompagner sa croissance à l’international, ETAP-Lab recrute. Vous aimez les challenges ?  Participez au développement commercial de notre entreprise ! Pré-requis : Bac+2/+3, avec une double compétence en biologie. Type de contrat : CDD de 6 mois avec évolution possible vers un CDI Localisation : Nancy (54)

Discover ETAP-Lab and other biotech businesses at an Afterwork evening on November 18th, organised by Biovalley France. Nicolas Violle will be delighted to meet you and tell you about what we do at ETAP-Lab. A rare opportunity to connect with key players in the Lorraine region. Thanks to BioValley France for making it happen! https://www.biovalley-france.com/fr/agenda/les-biotechs-du-coin-un-afterwork-dedie-au-foyer-lorrain/

Invisible but devastating, diabetes is a chronic disease affecting more than 463 million adults worldwide; it results in more than 1.5 million deaths each year. The number of patients is expected to reach 700 million by 2045 - so treating diabetes and its complications really is a major health challenge! On this day of solidarity and awareness, ETAP-Lab would like to show its support for diabetic patients. At ETAP-Lab, we’re already involved in fighting back against diabetes — our work on developing

Renewal of ETAP-Lab’s ISO 9001 certification (v2015)! A well-managed quality system is key to a high performance, trustworthy preclinical service. ETAP-Lab has been investing in quality management continuously for almost 10 years now. And for 10 years, ISO 9001 certification has recognized the excellence of our quality management system in the areas of consultancy and expertise as well as in the conduct of in vitro and in vivo preclinical research studies. Because we are always scrupulous in carrying out and monitoring our

Often hidden, psoriasis is a chronic disease affecting more than 125 million patients worldwide. It has a profound impact on quality of life. On this day of solidarity and awareness, ETAP-Lab would like to show its support for psoriasis patients. At ETAP-Lab, we’re already involved in fighting back against psoriasis—our work on developing and providing a translational preclinical research service is driven by our desire to improve quality of life for patients. ETAP-Lab is proud to support the preclinical development of new therapeutics

ETAP-Lab will be attending BioEurope 25 to 28 October. Our experts Dr. Ahmad Allouche (Head of In Vitro Biology) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Dermatology and Neurology, with Stroke, Alzheimer’s and Parkinson’s diseases. Please feel free to contact us to schedule a video conference. We’re hoping to meet you soon!

The poster we presented at the Alzheimer’s Association International Conference is now available on the ETAP-Lab website; it’s all about our innovative in vitro and in vivo models of Alzheimer's disease, which are based on the use of human A-Beta 1-42 oligomers. The poster focuses on the main results of the characterisation of the model in the aged mouse. This reproducible and translational model is a new tool for the evaluation of compounds targeting the early stages of Alzheimer's disease. We are

ETAP-Lab will present its new Alzheimer's model in the aged mouse at the Alzheimer's Association International Conference, to be held in Denver (USA) from 26 to 30 July 2021. Our expert, Dr. Ahmad Allouche, will be there to answer your questions about our in vitro and in vivo models of Alzheimer's disease, based on the use of human A-Beta 1-42 oligomers. Our poster entitled "New Alzheimer models for drug screening, based on improved human amyloid beta (1-42) oligomer preparations" (number #54152), presents

Low non-cytotoxic doses of ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity in NETRI’s microfluidic device coupled with MEA. This result is an important milestone towards a more relevant and physiological model of Alzheimer’s disease for drug screening and mechanistic studies. For more information download the Application Note #alzheimer #DrugScreening #microfluidics #neuroscience